Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model

• Published in: International journal of molecular sciences Vol. 25; no. 4; p. 2371
• Main Authors: Malinowska, Marcelina, Nowicka, Wioletta, Kloska, Anna, Węgrzyn, Grzegorz, Jakóbkiewicz-Banecka, Joanna
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2024
• Subjects: Analysis; Angiogenesis inhibitors; Animals; Blood-Brain Barrier; Brain; Cell cycle; Combination therapy; Disease Models, Animal; Enzyme Replacement Therapy - methods; Enzymes; Female; Females; Flavonoids; Gender differences; Gene therapy; Genetic disorders; genistein; Genistein - pharmacology; Genistein - therapeutic use; Glycosaminoglycans; Glycosaminoglycans - therapeutic use; Heart; Heparan sulfate; Iduronidase - therapeutic use; Isoflavones; laronidase; Liver; Males; Metabolic disorders; Mice; Mucopolysaccharidosis; Mucopolysaccharidosis I - drug therapy; mucopolysaccharidosis type I; Nervous system; Pathophysiology; Sexes; Spleen; Thrombin; Thrombin - therapeutic use; Transplants & implants; Poland; United Kingdom; Germany; glycosaminoglycans; combination therapy; laronidase; genistein; mucopolysaccharidosis type I
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25042371

Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by α-L-iduronidase deficiency. The standard treatment, enzyme replacement therapy with laronidase, has limited effectiveness in treating neurological symptoms due to poor blood-brain barrier penetration. An alternative is substrate reduction therapy using molecules, such as genistein, which crosses this barrier. This study evaluated the effectiveness of a combination of laronidase and genistein in a mouse model of MPS I. Over 12 weeks, MPS I and wild-type mice received laronidase, genistein, or both. Glycosaminoglycan (GAG) storage in visceral organs and the brain, its excretion in urine, and the serum level of the heparin cofactor II-thrombin (HCII-T) complex, along with behavior, were assessed. The combination therapy resulted in reduced GAG storage in the heart and liver, whereas genistein alone reduced the brain GAG storage. Laronidase and combination therapy decreased liver and spleen weights and significantly reduced GAG excretion in the urine. However, this therapy negated some laronidase benefits in the HCII-T levels. Importantly, the combination therapy improved the behavior of female mice with MPS I. These findings offer valuable insights for future research to optimize MPS I treatments.